Scott Hensley

Scott Hensley appears in the following:

Advisers to FDA weigh in on updated COVID boosters for the fall

Wednesday, April 06, 2022

The vaccines now in use are based on the form of the virus that circulated at the beginning of the pandemic and are less effective against the omicron variant. New options are in the works.


Pfizer-BioNTech will seek authorization for second COVID booster for older adults

Tuesday, March 15, 2022

Pfizer and BioNTech are planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people age 65 and older.


The FDA postpones a highly anticipated meeting on the Pfizer vaccine for young kids

Friday, February 11, 2022

"We believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization," FDA officials said in a statement.


The FDA authorizes a Pfizer booster shot for children ages 12 to 15

Monday, January 03, 2022

The authorization comes in the midst of an explosion of COVID-19 cases nationwide driven by the omicron variant — a surge that has brought a spike in pediatric hospitalizations.


The FDA has authorized Merck's COVID pill for home use — the second in two days

Thursday, December 23, 2021

The medicine, called molnupiravir, is taken twice a day for five days and works by preventing the virus from replicating. Merck says it will have 10 million packs available by the end of the month.


FDA authorizes 1st antiviral pill for COVID

Wednesday, December 22, 2021

In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.


CDC narrows use of J&J vaccine due to concerns about rare blood clots

Thursday, December 16, 2021

The agency implemented experts' advice because of a rare and sometimes fatal blood-clotting problem known as TTS. More than 16 million people in the U.S. have received a shot of the J&J vaccine.


Pfizer data shows that its COVID-19 pill is effective against severe disease

Tuesday, December 14, 2021

The research finds that the medicine, called Paxlovid, was effective in preventing hospitalization and death when taken by people with mild to moderate illness within a few days of symptoms.


An FDA panel supports Merck COVID drug in mixed vote

Tuesday, November 30, 2021

If the Food and Drug Administration authorizes use of the drug, called molnupiravir, it would be the first oral COVID-19 treatment that could be taken at home.


CDC backs expansion of COVID boosters for all adults

Friday, November 19, 2021

CDC Director Rochelle Walensky gave the green light to boosters just hours after a panel of vaccine advisors voted unanimously to recommend boosters for anyone 18 and older.


WATCH: Harvard-NPR panel on the fight to tame COVID

Friday, November 12, 2021

Watch an expert panel discuss the latest developments and challenges in the COVID-19 pandemic livestreamed at noon ET on Friday.


Moderna says new data supports its COVID vaccine for kids 6 to 11

Monday, October 25, 2021

Moderna says a study in kids 6 to 11 found two doses of the company's COVID-19 vaccine given 28 days apart produced a strong antibody response.


Pfizer-BioNTech COVID vaccine appears more than 90% effective in kids 5 to 11

Friday, October 22, 2021

The companies studied a 10 microgram vaccine dose in children 5 to 11, a third of the dose used for adults, to minimize side effects and because it still prompts a strong immune response.


CDC backs the rollout of COVID vaccine boosters from Moderna and J&J

Thursday, October 21, 2021

CDC Director Rochelle Walensky also endorsed a mix-and-match approach to boosters that would be flexible for patients and health care providers.


The FDA authorizes Moderna and J&J COVID vaccine boosters

Wednesday, October 20, 2021

The Food and Drug Administration also gave an OK to boosters that differ from the vaccine originally used to immunize people against COVID-19. A mix-and-match approach could ease the booster rollout.


An FDA panel of experts backs J&J COVID vaccine booster

Friday, October 15, 2021

A panel of experts voted to recommend that the Food and Drug Administration authorize a booster dose of the Johnson & Johnson COVID vaccine at least two months after the first shot.


Experts recommend that FDA should authorize Moderna COVID vaccine booster

Thursday, October 14, 2021

The recommendation applies to people 65 years and older, those 18 to 64 who are at high risk of severe COVID and those whose work or institutional exposure puts them at high COVID risk.


FDA analysis of J&J COVID vaccine booster sets the stage for public hearing

Wednesday, October 13, 2021

Johnson & Johnson has asked the Food and Drug Administration to authorize a booster for people 18 and older six months after initial immunization, with an option to vaccinate after two months.


Moderna and J&J say their data supports COVID vaccine boosters

Tuesday, October 12, 2021

The Food and Drug Administration released briefing documents Tuesday on booster shots for the Moderna and Johnson & Johnson COVID vaccines ahead of a two-day advisory meeting that starts Thursday.


The FDA OKs Pfizer-BioNTech Booster For People 65+ Or At High Risk For Severe COVID

Wednesday, September 22, 2021

A third shot of the vaccine can be given at least six months after the two-dose regimen, according to the authorization. A booster rollout could begin this week.